1. Home
  2. SATL vs XERS Comparison

SATL vs XERS Comparison

Compare SATL & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Satellogic Inc.

SATL

Satellogic Inc.

HOLD

Current Price

$7.95

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$6.45

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SATL
XERS
Founded
2010
2005
Country
United States
United States
Employees
154
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SATL
XERS
Price
$7.95
$6.45
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
$5.50
$10.83
AVG Volume (30 Days)
7.9M
1.6M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.01
Revenue
N/A
$49,590,000.00
Revenue This Year
$88.89
$34.37
Revenue Next Year
$56.98
$22.86
P/E Ratio
N/A
$626.50
Revenue Growth
N/A
142.67
52 Week Low
$1.26
$4.30
52 Week High
$8.90
$10.08

Technical Indicators

Market Signals
Indicator
SATL
XERS
Relative Strength Index (RSI) 59.31 56.59
Support Level $3.17 $6.26
Resistance Level $8.18 $7.21
Average True Range (ATR) 0.75 0.29
MACD 0.06 0.01
Stochastic Oscillator 69.81 48.39

Price Performance

Historical Comparison
SATL
XERS

About SATL Satellogic Inc.

Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: